ArticleCancer cell international2025
TMEM71 is crucial for cell proliferation in lower-grade glioma and is linked to unfavorable prognosis.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Single-cell analysis identifies a VIM+ glioma stem-like vascular-immune state linked to myeloid OSM signaling and CEBPD activity.Frontiers in immunology · 2026Article
- A histone-centric multi-omics study shows that increased H3K4 methylation sustains triple-negative breast cancer phenotypes.Nature communications · 2025Article
- Single‑cell RNA sequencing reveals TMEM71 as an immunomodulatory biomarker predicting immune checkpoint blockade response in breast cancer.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTransmembrane protein 71 (TMEM71) is implicated in multiple cellular physiological functions and has been demonstrated to be crucial in the advancement of different cancerous growths. However, its specific function in low-grade glioma (LGG) remains unclear.
methodsWe examined the expression patterns and prognostic importance of TMEM71 in various types of cancer by using pan-cancer analysis. The analyses of the correlations between TMEM71 expression and clinicopathological characteristics, prognosis, biological functions, immune characteristics, and genomic variations in LGG were conducted based on its expression patterns. Finally, the expression level and biological function of TMEM71 in LGG were verified by executing in vitro studies.
resultsAbnormal elevation of TMEM71 expression level was associated with poor prognosis of many tumors including LGG. Both multivariate and univariate Cox regression analyses indicated that the expression of TMEM71 served as a standalone prognostic biomarker for LGG. The levels of TMEM71 expression were associated with immune-related characteristics, infiltration of immune cells, immune checkpoint genes (ICPGs) expression, and tumor mutation burden (TMB) in patients with LGG. In laboratory studies, elevated levels of TMEM71 were found to be involved in activating the JAK2/STAT3 pathway, promoting CCAAT/Enhancer Binding Protein D (CEBPD) expression, and ultimately affecting the growth and motility of LGG cells.
conclusionTMEM71 is an independent prognostic indicator for LGG and is strongly associated with the growth of LGG cells, positioning it as a potential novel target for treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.